Ocular hypertension is the increased intraocular pressure in the eyes. If left untreated, the disease can further lead to glaucoma or permanent loss of vision. Clinically, it is estimated that 21 mmHg eye pressure or greater denotes the occurrence of ocular hypertension. The excessive aqueous humour production, inadequate drainage of aqueous humour, eye trauma, and steroidal medications are some of the causes of ocular hypertension. Ocular hypertension can be treated by medication that increases aqueous humour outflow or decreases aqueous humour production. Santen Pharmaceutical Co., Ltd. is in the process of developing DE-117 as a prostaglandin E EP2 receptor agonist for the treatment of ocular hypertension. Envisia Therapeutics, Inc. is in the process of developing ENV-515 as a prostaglandin F2 alpha agonist for the treatment of ocular hypertension. Some of the companies having the pipeline of ocular hypertension include Santen Pharmaceutical Co., Ltd., Shire plc, Ocular Therapeutix, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.